Hydroxychloroquine is NOT Effective for Burning Mouth Syndrome
Hydroxychloroquine has no established role in treating idiopathic burning mouth syndrome (BMS) and should not be used for this indication. There is no evidence—neither in clinical trials nor in treatment guidelines—supporting its efficacy for BMS, and the drug carries significant risks that are unjustifiable without proven benefit.
Why Hydroxychloroquine is Not Indicated
Complete Absence of Evidence
No studies have evaluated hydroxychloroquine for BMS treatment. Comprehensive reviews of BMS therapies spanning 15-20 years of literature identify multiple treatment modalities including antidepressants, alpha-lipoic acid, clonazepam, capsaicin, anticonvulsants, cognitive therapy, and laser therapy—but hydroxychloroquine is never mentioned as a therapeutic option 1, 2, 3, 4, 5.
The systematic review of BMS treatment modalities analyzed 29 randomized clinical trials published between 1996-2016, categorizing treatments into antidepressants, alpha-lipoic acid, phytotherapeutic agents, analgesic/anti-inflammatory agents, and non-pharmacological therapies—hydroxychloroquine appears in none of these categories 5.
Mechanism Mismatch
Hydroxychloroquine's pharmacologic actions do not address BMS pathophysiology. Hydroxychloroquine is an antimalarial and immunomodulatory agent used for autoimmune conditions like systemic lupus erythematosus and rheumatoid arthritis 6, 7.
BMS is a neuropathic pain disorder, not an autoimmune or inflammatory condition. Primary (idiopathic) BMS is characterized by burning sensation without clinically apparent mucosal alterations or underlying autoimmune pathology 3.
The European League Against Rheumatism guidelines recommend hydroxychloroquine for Sjögren's syndrome but explicitly state it does NOT improve subjective or objective oral dryness outcomes—the closest oral symptom to BMS studied 6.
Significant Risks Without Benefit
Retinal Toxicity
Irreversible vision loss can occur after >2 years of continuous use due to chloroquine retinopathy, the most serious long-term adverse effect 7.
Baseline ophthalmologic examination is mandatory before initiating therapy, with annual screening beginning after 5 years for low-risk patients 7.
Other Adverse Effects
Common side effects include gastrointestinal disturbance, headache, dizziness, blurred vision, and pruritus 7.
QT interval prolongation requires baseline ECG monitoring 7.
Rare but serious effects include elevated liver enzymes, exacerbation of psoriasis, and cardiac toxicity 7.
The drug is absolutely contraindicated in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency 7.
Evidence-Based Treatment Algorithm for BMS
First-Line Approaches
Topical clonazepam shows good short-term results for pain relief, though not a definitive cure 4.
Alpha-lipoic acid demonstrates good results in multiple studies, though long-term data on complete symptom remission remain limited 4, 5.
Second-Line Options
Antidepressants (tricyclic antidepressants like amitriptyline, or duloxetine) show promising results in systematic reviews 1, 5.
Anticonvulsants (gabapentin or pregabalin) are established options 1.
Low-dose aripiprazole has emerging evidence 1.
Adjunctive Therapies
Cognitive behavioral therapy is reported as a good and lasting therapeutic option with no side effects, and can be combined with pharmacologic therapy 4.
Capsaicin (topical) has evidence from randomized controlled trials 3.
Critical Diagnostic Step
Rule out secondary causes before diagnosing primary BMS: vitamin deficiencies (B12, folate, iron), zinc deficiency, hormonal changes, xerostomia, oral candidiasis, geographic tongue, lichen planus, medication side effects, and psychological factors 3.
When local, systemic, or psychological factors are identified and treated, significant clinical improvement usually occurs 3.
Common Pitfall to Avoid
Do not prescribe hydroxychloroquine simply because a patient with BMS has positive autoantibodies (ANA, anti-Ro/La, RF) without meeting criteria for systemic autoimmune disease. Isolated autoantibody positivity does not reliably predict clinical disease, and there is no evidence that hydroxychloroquine alters this natural history 8. The monitoring burden and toxicity risks are unjustifiable in asymptomatic individuals or those with BMS alone 8.